Skip to main content

Table 4 Neonatal outcomes in different groups

From: Effect of letrozole cotreatment in progestin-primed ovarian stimulation on IVF/ICSI outcomes in POSEIDON group 3 and 4 poor responders: a retrospective cohort study

Variables

POSEIDON Group 3

P value

POSEIDON Group 4

P value

PPOS group n = 78

PPOS + LE group n = 111

PPOS group n = 154

PPOS + LE group n = 214

No. of live birth cycle

24

42

 

16

22

 

No. of neonatal

26

42

 

19

22

 

Gestational age (weeks)

38.40 ± 1.53

38.01 ± 2.35

0.461

37.00 ± 2.20

38.68 ± 1.09

0.003*

Mean birth weight (g)

3189.23 ± 535.54

3182.86 ± 703.01

0.969

2921.58 ± 608.18

3332.27 ± 292.96

0.013*

Delivery mode, n (%)

  

1.000

  

1.000

Vaginal delivery

4/24 (16.67)

7/42 (16.67)

 

0

1/22 (4.54)

 

Cesarean section

20/24 (83.33)

35/42 (83.33)

 

16/16 (100.00)

21/22 (95.45)

 

Gender, n (%)

  

0.583

  

0.829

Male

16/26 (61.54)

23/42 (54.76)

 

11/19 (57.89)

12/22 (54.54)

 

Female

10/26 (38.46)

19/42 (45.24)

 

8/19 (42.11)

10/22 (45.45)

 

Maternal and neonatal complications, n (%)

Preterm birth

1/24 (4.17)

3/42 (7.14)

1.000

4/16 (25.00)

2/22 (9.09)

0.217

Gestational Diabetes Mellitus

0

3/42 (7.14)

0.295

1/16 (6.25)

1/22 (4.54)

1.000

Hypertensive disorders of pregnancy

2/24 (8.33)

3/42 (7.14)

1.000

2/16 (12.50)

1/22 (4.54)

0.562

Placenta previa

1/24 (4.17)

3/42 (7.14)

1.000

0

0

N/A

Premature rupture of membranes

0

1/42 (2.34)

1.000

0

0

N/A

Macrosomia

1/26 (3.85)

2/42 (4.76)

1.000

0

1/22 (4.54)

1.000

Low birth weight

0

0

N/A

0

0

N/A

Pneumonia of newborn

0

2/42 (4.76)

0.521

2/19 (10.53)

1/22 (4.54)

0.588

Jaundice of newborn

1/26 (3.85)

3/42 (7.14)

1.000

3/19 (15.79)

2/22 (9.09)

0.649

Birth defect in total

0

0

N/A

0

0

N/A

  1. Data were presented as mean ± SD, median (25th percent, 75th percent) and n (%)
  2. N/A, not applicable